for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Nicox Completes End-of-Phase 2 Meeting With the U.S. FDA

March 5 (Reuters) - NICOX SA:

* NICOX’S POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FDA SETS STAGE FOR NCX 470 PHASE 3 PROGRAM IN GLAUCOMA

* MONT BLANC TRIAL, FIRST PHASE 3 CLINICAL TRIAL OF NCX 470, IS EXPECTED TO START BY END OF Q2 2020

* WE ARE ON TRACK TO INITIATE FIRST PIVOTAL CLINICAL TRIAL BY END OF Q2 2020

* TOP-LINE RESULTS EXPECTED IN Q3 2021 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up